Mineralys Therapeutics (NASDAQ:MLYS) Insider Sells $13,033.28 in Stock
by Michael Walen · The Markets DailyMineralys Therapeutics, Inc. (NASDAQ:MLYS – Get Free Report) insider David Malcom Rodman sold 416 shares of the company’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $31.33, for a total transaction of $13,033.28. Following the completion of the sale, the insider directly owned 69,792 shares in the company, valued at approximately $2,186,583.36. The trade was a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
David Malcom Rodman also recently made the following trade(s):
- On Wednesday, April 15th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.66, for a total transaction of $175,585.68.
- On Monday, April 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.54, for a total transaction of $373,099.32.
- On Thursday, April 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.38, for a total transaction of $59,414.60.
- On Thursday, March 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.37, for a total transaction of $173,744.76.
- On Friday, March 13th, David Malcom Rodman sold 14,058 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.26, for a total transaction of $369,163.08.
- On Monday, March 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $26.84, for a total transaction of $58,269.64.
- On Tuesday, February 17th, David Malcom Rodman sold 417 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.59, for a total transaction of $11,505.03.
- On Thursday, February 12th, David Malcom Rodman sold 6,349 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $28.99, for a total transaction of $184,057.51.
- On Friday, February 13th, David Malcom Rodman sold 14,055 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $27.44, for a total transaction of $385,669.20.
- On Monday, February 9th, David Malcom Rodman sold 2,171 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $30.21, for a total transaction of $65,585.91.
Mineralys Therapeutics Stock Down 1.5%
MLYS opened at $28.49 on Friday. Mineralys Therapeutics, Inc. has a twelve month low of $12.59 and a twelve month high of $47.65. The company has a 50-day moving average price of $27.24 and a 200 day moving average price of $34.00. The company has a market cap of $2.35 billion, a PE ratio of -12.02 and a beta of 0.69.
Mineralys Therapeutics (NASDAQ:MLYS – Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. As a group, sell-side analysts expect that Mineralys Therapeutics, Inc. will post -2.28 earnings per share for the current year.
Analysts Set New Price Targets
Several research firms recently weighed in on MLYS. Wall Street Zen upgraded shares of Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. HC Wainwright set a $56.00 price target on shares of Mineralys Therapeutics and gave the stock a “buy” rating in a research report on Tuesday, March 10th. Jefferies Financial Group restated a “hold” rating and set a $30.00 price target on shares of Mineralys Therapeutics in a research report on Friday, March 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Tuesday. Finally, Bank of America increased their price objective on shares of Mineralys Therapeutics from $46.00 to $51.00 and gave the company a “buy” rating in a report on Friday, March 13th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $49.14.
Read Our Latest Stock Analysis on Mineralys Therapeutics
Institutional Trading of Mineralys Therapeutics
A number of hedge funds have recently bought and sold shares of the business. Smartleaf Asset Management LLC raised its holdings in Mineralys Therapeutics by 198.2% in the 3rd quarter. Smartleaf Asset Management LLC now owns 1,017 shares of the company’s stock valued at $40,000 after acquiring an additional 676 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Mineralys Therapeutics by 4.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,085 shares of the company’s stock valued at $271,000 after acquiring an additional 702 shares during the last quarter. Navalign LLC acquired a new stake in Mineralys Therapeutics in the 4th quarter valued at about $33,000. Velan Capital Investment Management LP raised its holdings in Mineralys Therapeutics by 0.6% in the 3rd quarter. Velan Capital Investment Management LP now owns 175,600 shares of the company’s stock valued at $6,659,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Royal Bank of Canada raised its holdings in Mineralys Therapeutics by 262.3% in the 4th quarter. Royal Bank of Canada now owns 1,529 shares of the company’s stock valued at $56,000 after acquiring an additional 1,107 shares during the last quarter. Institutional investors and hedge funds own 84.46% of the company’s stock.
About Mineralys Therapeutics
Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.